Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 190-195

  Wallace, Zachary S ^a   Mattoo, Hamid ^a   Carruthers, Mollie ^a   Mahajan, Vinay S ^a   Della Torre, Emanuel ^a   Lee, Hang ^a   Kulikova, Maria ^a   Deshpande, Vikram ^a   Pillai, Shiv ^a   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN G4; RITUXIMAB; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED DISEASE; MALE; MEMORY CELL; NEPHELOMETRY; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PLASMABLAST; REMISSION; AUTOIMMUNE DISEASES; BLOOD; CASE CONTROL STUDY; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PLASMA CELLS; SENSITIVITY AND SPECIFICITY;

EID: 84918540903     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205233     Document Type: Article

References (37)

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539-51.
2. Carruthers MN, Stone JH, Khosroshahi A. The latest on IgG4-RD: a rapidly emerging disease. Curr Opin Rheumatol 2012;24:60-9.
3. Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012;91:49-56.
4. Ferry JA, Deshpande V. IgG4-related disease in the head and neck. Semin Diagn Pathol 2012;29:235-44.
5. Plaza JA, Garrity JA, Dogan A, et al. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol 2011;129:421-8.
6. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061-7.
7. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-92.
8. Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int 2008;58:465-70.
9. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012;22:1-14.
10. Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease-delayed treatment induces fibrosis progression. Rheumatology (Oxford) 2013;52:679-83.
11. Brenner I, Roth S, Puppe B, et al. Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression. Mod Pathol 2013;26:1568-76.
12. Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 2011;64:237-43.
13. Ryu J, Ryohei H, Sekiguchi H, et al. Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheum Dis 2012:232960.
14. Carruthers M, Khosroshahi A, Augustin T, et al. Diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015;74:14-8.
15. Koike T. IgG4-related disease: why high IgG4 and fibrosis?. Arthritis Res Ther 2013;15:103.
16. Tsuboi H, Matsuo N, Iizuka M, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res Ther 2012;14:R171.
17. Zen Y, Nakanuma Y. Pathogenesis of IgG4-related disease. Curr Opin Rheumatol 2011;23:114-18.
18. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012;91:57-66.
19. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 2010;10:236-47.
20. Stroopinsky D, Katz T, Rowe JM, et al. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012;61:1233-41.
21. Harada Y, Kawano MM, Huang N, et al. Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol 1996;92:184-91.
22. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
23. Fink K. Origin and function of circulating plasmablasts during acute viral infections. Front Immunol 2012;3:1.
24. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
25. Odendahl M, Keitzer R, Wahn U, et al. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003;62:851-8.
26. Kerkman PF, Rombouts Y, Van Der Voort EI, et al. Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1259-63.
27. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63:3038-47.
28. Iwata S, Saito K, Hirata S, et al. Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy. Ann Rheum Dis 2012;71:2058-9.
29. Carruthers MN, Stone JH, Deshpande V, et al. Development of an IgG4-RD Responder Index. Int J Rheumatol 2012;2012:259408.
30. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013;62:1607-15.
31. Khosroshahi A, Cheryk L, Carruthers M, et al. Spuriously low serum IgG4 concentrations caused by the prozone phenomenon in IgG4-related disease. Arthritis Rheumatol 2014;66:213-17.
32. Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Curr Opin Rheumatol 2011;23:72-3.
33. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58:1504-7.
34. Hosomi S, Oshitani N, Kamata N, et al. Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clin Exp Immunol 2011;163:215-24.
35. Owczarczyk K, Lal P, Abbas AR, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011;3:101ra92.
36. Tarlton NJ, Green CM, Lazarus NH, et al. Plasmablast frequency and trafficking receptor expression are altered in pediatric ulcerative colitis. Inflamm Bowel Dis 2012;18:2381-91.
37. Maillette De Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 2013;57:2390-8.